Well I would think they loaded up the pipeline of the new product to distributors so the rev and earnings will look very positive for 1 quarter.
The recent low of $4.78 and subsequent recovery during the day sets the stage for a firm floor for the stock to advance. I would expect a retest of $5 and then a significant move to the upside from there. One perplexing issue continues to be the large short position, these guys are usually right. Maybe Bigs theory of a large owner hedging could explain this, but thats just a guess. Anyway, accumulation at the current price seems safe to me barring any negative news. I would expect the test of the lows to occur over the next month or so and would personally view it as a buying opportunity.
Well you'll discover that the market for the last 4 years has been pretty much up across the board and all stock rising with the tide. At some point that will change and make stock picking much more important
Was potentially achieved today. The fact that the stock broke through $4.85 the recovered above 5 suggests the downtrend may have just reversed itself. It may test the low one more time and if it holds I would expect a decent short covering rally. Now may be the time to buy.
All you seem very good at is insulting people you don't agree with and don't even know. Must make you feel good about yourself, it shows the kind of person you are. The people I know in the medical people care about others and not vindictive, self centered bullies as you continue to show yourself to be.
My suggestion for investments like this is to be willing to invest an amount that you could loose completely, similar to what a venture firm would do where they invest in 10 companies with the expectation of 1 or 2 making a 10 bagger while the others go to zero. If SSH works out there is clearly a large market, but the company is a long long way from proving they can meet that markets needs.
I also invest in high risk speculative issues, but over the last 50+ years of investing I learned not to "fall in love" to soon in a company because almost always there are hidden risks that will drive the shares down. So my approach is to take a small position to make sure I follow the company closely and wait for when the time is right to jump in about the time others are jumping off the tall buildings because they have lost so much. The problem with SSH will be the massive dilution they will need to do to raise the cash they will need. If you want to see a company with great potential that was screwed up because of a self centered CEO, look at MELA. Won best tech from Cleveland Clinic, but the CEO drove it into the ground because he failed to have and execute a viable clinical and go to market strategy.
By what he is doing to raise money. When he was raising the $50 million at $10.50 he had wall street investors so excited that they had subscriptions for more than $100 million and had to close the offering early because big investors did not want to have to take lower allocations. Now I'm sure they all wish they had gotten lower allocations. The guy raised the money and I'll give him credit for doing so but it was sold on the back of an aggressive clinical study. He told his investors that the money raised would get the company through US trails which he now says will not occur because of the slow enrollment. I expect ultimately investor lawsuits because of his over selling what the company can deliver on.
I agree with you and you unlike ex14142000 you do not insult people whom have a different opinion, and don't act like a bully.
One challenge that is facing companies in the USA is the significantly increased conservatism of the FDA over the last several years for medical devices. The FDA is requiring more data and requiring sham studies in many cases. This translates into time and money and requires you make sure your study design is flushed out or you will be faced with restarting your trial from the beginning should you fail to meet you trial end points.
Newbryc3 1st I'll say that your response is very intelligent and worth reading because what you say makes sense to me. Ex14142000's discussions are rubbish and not worth the time to read. That said, my mother has end stage chf, she's 92 and little options for anything except trying to maintain the proper water balance as her heart weakens over time. I believe an effective device will be huge for helping patients once it is proven clinically. What's amazing to me is how naive people are about where exactly this company is at. Sure the few implants are encouraging but to risk a major part of your net worth on this company at this stage is highly risky. And that's my entire basis of my discussion, it's to make investors aware of the real risks this company has. I have interacted with the CEO on several occasions and it's that interaction that has made me believe this company has a lot more risk than is apparent to the everyday investor. The guy does not listen to people all he does is talk talk talk. I could not believe it. Anyway, I do appreciate your perspective and look forward to further dialog with you. Be careful with investing in this, it seems it is headed much lower.
He (or she) clearly just keeps hyping the company like its CEO. If you follow this persons suggestions you would have lost a significant % of your investment. This person has shown to have no credibility.
This company has had such a small number of patients to conclude any statistical conclusion as to the overall viability of the device effectiveness. For the long investors just pray this inexperienced company has designed their clinical trial in a way that will give conclusive results that this therapy is viable.
I'm not on board because their CEO hypes the company prospects luring investors into false promises and he is doing this either because he he is dishonest or incompetent to handle this complex of a medical device clinical trial. And If you had the intelligence you seem to convey then you would understand the significant implications of Medtronic's failed renal denervation study. It failed because the study design was flawed and they did not find out about it until all the patient procedures were completed because of the blinded nature of the study.
So what are the risks of the SSH clinical design, are there any? According to you its all in the bag. And this perspective is completely naive.
The most likely future for this company will be a continuous failure to meet their milestones and continued investor disappointment, driving the stock price down while the company's burn rate continues to increase causing them to have to dilute existing shareholders further. Then there is the risk of a reliability problem with their device leading to a recall and when that happens you will be able to pick up shares at a much lower price.
Does not define a scientific sample large enough to say anything accept it is encouraging. Once there is data on 300-400 patients in a blinded randomized trial, then draw your conclusions. And hope like heck they designed the clinical trial properly and did not screw it up like Medtronic's renal denervation trial, that wasted 2+ years with a faulty clinical trial design.